eGFR in changing drug regimensBMJ 2007; 334 doi: https://doi.org/10.1136/bmj.39247.716806.3A (Published 21 June 2007) Cite this as: BMJ 2007;334:1287
- Jeffrey K Aronson, reader in clinical pharmacology
- Department of Clinical Pharmacology, Radcliffe Infirmary, Oxford OX2 6HA
Giles and Fitzmaurice did not discuss another use of estimated renal function—to guide changes in the dosage regimens of drugs that are eliminated unchanged by the kidneys, that have active metabolites that are eliminated by the kidneys, or whose pharmacodynamic effects are affected by renal insufficiency.1 This is particularly important for drugs that have a low therapeutic index.
Recommendations about drug dosage regimens given in manufacturers' summaries of product characteristics …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial